accidently discovered a new form of extracellular membrane vesicles. "Examining biopsy tissue from glioblastoma patients from the operating room, we saw their cells were covered with vesicles that contained tumor RNA that was protected from rapid degradation in the bloodstream. When these glioblastoma vesicles were added to human brain endothelial cells, they started forming tubules before our eyes within a day. We had found a very potent mechanism of promoting tumor growth that we hadn't even known existed," said Breakefield.
The Breakefield laboratory's findings, published in the December 2008 Nature Cell Biology, raised new questions. Could they pick out glioblastoma extracellular vesicles in blood samples? Examining blood serum from 25 glioblastoma patients confirmed tumor vesicles in all patients by virtue of a glioblastoma-specific activating mutation for the epidermal growth factor receptor.
"This biofluid-based diagnostic technology provides a liquid biopsy for glioblastoma," said Breakefield. "It can be used to monitor tumor progression and for disease risk stratification." She is participating in a 10-center glioblastoma biomarker project that is part of a clinical trial looking for therapeutics to suppress tumor activity.
"RNA and nucleic acid in exosomes can be used to noninvasively interrogate what is happening in the tumor in real time," said Skog.
Skog, now director of research at Exosome Diagnostics in New York, and colleagues are part of a multi-institution clinical trial led by the Prostate Cancer Foundation to develop a more effective diagnostic test for prostate cancer by evaluating RNA and nucleic acid transcripts released into the urine in microvesicles.
Although the prostate cancer trial is farthest along, another is looking for neurodegenerative biomarkers in cerebrospinal fluid for Alzheimer disease and Parkinson disease. They are also part of a multi-institution consortium looking at brain tumor mutations such as EGFRv3 in cerebrospinal fluid and plasma to diagnose glioma.
NIH Encourages Exosome Research With Grants
The new understanding of extracellular RNA (exRNA) and extracellular vesicles (exosomes) suggest potential uses in diagnosis, prognosis, and treatment of several diseases. "For the past decades, exosomes have been viewed as inconsequential," said Danilo A. Tagle, Ph.D., associate director for special initiatives at the National Center for Advancing Translational Sciences at the National Institutes of Health. "Through a convergence of advances in sequencing technology and cell biology research, it was recently learned that extracellular vesicles are actually filled with RNA, DNA, proteins, and lipids and are very important signaling molecules."
Tagle was one of the organizers of an NIH working group that identified exRNA as an area for multidisciplinary research that could have tremendous impact. After an extensive review by NIH leadership, the NIH Common Fund announced a 5-year, $133 million funding opportunity in May 2012 to stimulate and support multidisciplinary study in five areas of exRNA communication.
The grants are for the following purposes:
• Development and demonstrate the potential for clinical utility of exRNA as therapeutic agents.
• Creation of a data-management resource/ repository.
• Development of reference profiles of exRNA from healthy human blood and body fluid samples.
• Determine the principles that guide the selection of regulatory RNA molecules for extracellular transport and determine their function.
• Identify and qualify exRNA-based biomarkers from human body fluids to diagnose and monitor disease progression and response to therapy. Yet, while medical center palliative-care programs continue to gain visibility and grow in number across the country, experts say, many obstacles remain to integrating such programs into mainstream cancer care, particularly early in treatment.
One reason, some say, is that palliative care has an image problem and is misunderstood.
"The Temel study was our gamechanger," noted Rebecca Kirch, J.D., director of Quality of Life and Survivorship at the American Cancer Society. "Very rapidly after that clinical trial, the Joint Commission (the nation's preeminent health care-accreditation agency), the Commission on Cancer, and ASCO began to pay more attention and to endorse quality care standards and guidance supporting palliative-care integration in oncology. But our biggest hold-up to wider acceptance has been public perception. Most people are not knowledgeable about palliative care. In contrast, many health care providers and the public continue to believe that palliative care is what you do when there is nothing left to do. They think that palliative care is the same as hospice. It's not."
"It seems that no matter what we do, people see palliative care as the end of life," said geriatrician Ann Berger, M.D., chief of pain and palliative care at the National Institutes of Health. "Palliative care should begin at diagnosis, even if the patient is going to be cured. It's not only about end of life-it's about quality of life, including symptom management, and the physical, social, psychological and spiritual aspects of care." "Messaging and language matter a great deal-for purposes of public perception, for NIH grants, for professional training, and public policy," said Kirch. "To change the psyche of the nation to think of quality of life as a priority alongside treatment, we need to find a way to get oncologists to think of palliative care specialists as colleagues and not last resorts."
Resources, Training Lacking
Misconceptions aside, Jennifer Temel, who sees the ASCO report as a strong statement supporting early and universal palliative care, worries that resources are lacking and hindering its widespread use.
"Realistically, the nation does not have sufficient palliative-care staffing and infrastructure to provide care for all patients," she said. "The ASCO provisional clinical opinion (PCO) brought the issue to the forefront in medicine and presents it as an option for all patients with metastatic cancer. We need to train more physicians to specialize in palliative medicine, and the PCO helps more people understand that palliative care isn't necessarily end-of-life care. It's a wake-up call for more funding and training, and additional infrastructure on both local and national levels."
Improved physician training in medical school and residencies will help change the image of palliative care among doctors and increase its everyday use, said Jamie Von Roenn, M.D., professor of medicine at the Feinberg School of Medicine and director of palliative care at Northwestern University. Although it is a specialty, "we need physicians and oncologists to be trained in primary palliative care, including skills in pain management, and in the basic assessment of anxiety and depression." Von Roenn has another concern: Too often, physicians and oncologists think they know how to provide palliative care, when in reality, they may not.
"We can't change perception and increase the use of palliative care unless we change the standards of what we expect physicians to have competencies in from medical school, residencies, and fellowships," said Diane E. Meier, M.D., professor of geriatrics and palliative medicine at the Mount Sinai School of Medicine. Meier, also director of the Center to Advance Palliative Care, a national advocacy organization, said that currently, there are few "requirements for physicians to demonstrate skills in patient communication, in the management of pain and other symptoms, and in coordinating care across settings in the course of an illness." One result of this lack of training, she said, is that patients too often "deal with untreated pain, a lack of communication with doctors and families about what to expect as a disease progresses, and a high rate of hospital readmissions."
Although Mitchell acknowledged that many oncologists possess variable palliative-care skills, others contend that many are very well trained.
"I think that most experienced oncologists understand that palliative care is not end-of-life care and that it should be integrated into the care of patients almost from the beginning of treatment," said Richard Schilsky, M.D., who recently left the University of Chicago to join ASCO as its chief medical officer. "Most well-trained oncologists have significant skills in palliative and supportive care as part of daily practice and are comfortable prescribing pain and antinausea medications."
Still, few receive formal training in palliative care, he admitted, noting "it's mostly on-the-job training." Not only are there too "All of this interest in palliative care is related to the fact that more people are living with cancer than ever before."
Downloaded from https://academic.oup.com/jnci/article-abstract/105/6/372/1021651 by guest on 27 October 2018 few palliative-care specialists to meet patient and family needs, he said, they are frequently unavailable to most oncologists in community clinical practice. "The emphasis should be on training more specialists to support oncologists, and be sure that the oncologists themselves have the necessary knowledge. We've all seen that patient who has refractory pain or unrelenting nausea; those are situations where access to palliative care specialists can be extremely valuable."
Making Palliative Care Mainstream
Although improved training may help increase the use of palliative care, Von Roenn suggested emulating a model developed by Cancer Care Ontario in which newly arriving cancer patients are screened through questionnaires. "Every patient who walks into a cancer center there fills out a questionnaire about his or her care, asking about . . . dealing with psychosocial issues, dietary concerns, and other issues related to quality of life," she said, which becomes part of the patient's record.
Meier supported this approach. "Adopt the stance that palliative care is a core element of quality care," she said. "We need to screen all patients for depression symptoms, for possible pain issues, caregiver stress, family understanding of the illness and what to expect, and ask if there are adequate resources at home. If palliative-care needs are identified, there should be protocols automatically triggered by the screening."
The Joint Commission this year released a new certification in medical centers and hospitals for palliative care, she noted. She said that roughly two-thirds of U.S. hospitals have a palliative-care team on staff, and perhaps in the next several years, this will become a condition of Joint Commission accreditation. "I hope that having a qualified palliative-care team becomes a necessary step for accreditation. When that happens, it becomes a more universal approach."
Although the field continues to struggle somewhat with wider acceptance by oncologists, and a lack of needed training programs, financial barriers remain to contend with. Temel's New England Journal study and a subsequent Journal of Clinical Oncology report she cowrote suggested potential cost savings from early palliative care.
At the 2012 annual ASCO meeting, her group presented data showing that overall, there were cost savings from cutting the use of chemotherapy in the last few months of life, along with fewer, and briefer, hospital stays and in referring patients to hospice. Although these savings were offset somewhat by increasing outpatient expenses, savings averaged about $2,000 per patient.
Yet paradoxically, despite overall savings, oncologist reimbursement for palliativecare services continues to lag behind that for other treatments, such as chemotherapy. "They are nowhere near being on par with fee-for-service cancer treatment," noted Kirch, from the American Cancer Society.
We have to train health professionals, change the payment system, and change the awareness of the nation to demand this type of integrated and patient-centered care because that is what will motivate change," she said. "Patients, families, and caregivers need to be asked about what is important to them, and health professionals need to consider the implications of that information in helping patients make informed decisions and focus on what is happening in the course of their illness, treatment, survivorship, and death. There's a steady drumbeat of interest now building in palliative care, and we have to seize the moment and get people to embrace it."
